SAN DIEGO--(BUSINESS WIRE)--Melanoma specialists at Moores UCSD Cancer Center are recruiting patients into a large Phase 3 study to evaluate the safety and effectiveness of Allovectin-7®, an investigational product for advanced melanoma. If Allovectin-7® is found to be safe and effective in clinical trials, it may offer patients a new option for fighting melanoma that has progressed to stage 3 or stage 4.